A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate
NCT07124156
Infections, Malaria
View Trial DetailsNCT Number: NCT07456969
This project supports the development of a non-invasive diagnostic tool for malaria, focusing on validating the link between VOCs (volatile organic compounds) and malaria infection using thermodynamic sensors. This technology aims to provide rapid, painless alternatives to blood-based diagnostics, enabling malaria detection without invasive sampling.
Trace Sensing has already identified six potential VOC biomarkers based on published literature specific for malaria. Two of these are part of the company's existing library and can already be detected in purified form by the TRACE-E device, while the others are under active evaluation. To confirm the suitability of the selected VOC biomarkers for diagnosing malaria and strengthen the detection algorithm, high-quality, robust clinical data from well-characterized biological specimens are required. In partnership with Gondar University in Ethiopia, breath samples will be collected from individuals (12 years and older) suspected of having malaria presenting at two health clinics. PCR performed on blood samples will serve as reference method to confirm infection status, while non-invasive clinical breath tests will be performed using the TRACE-E device.
The resulting data will confirm whether the six candidate malaria VOC biomarkers can be detected in patient breath, and if other VOC biomarkers can be detected as well. This study will therefore act as a malaria VOC biomarker confirmation study.
Trial opening soon.
Get Notified12 year and older
All sexes
Observational
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Aged 12 years or older
Presenting at the study site with fever (37.5 degrees and above)
Freely agreeing to participate by providing informed consent (and assent, if applicable)
Exclusion criteria
Presence of symptoms and signs of severe illness and/or central nervous system infections.
Presenting with any condition that prevents adequate breath collection:
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Severe respiratory illness
Inability to follow instructions
Patient lacking capacity to provide informed consent.
Prior antimalarial treatment within the last 14 days.
Time frame: From June 2026 to September 2026
Detection rate of the six predefined malaria VOC biomarkers in breath from PCR-confirmed malaria-positive and negative participants, as measured by TRACE-E.
Contact information is provided by the study sponsor or research team.
Foundation for Innovative New Diagnostics, Switzerland
Other
Data Collection Support for a Non-invasive Malaria Diagnostic Tool Using Volatile Organic Compounds (VOC) in Gondar, Ethiopia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07124156
Infections, Malaria
View Trial DetailsNCT07520279
Alphavirus Infections, Arbovirus Infections
San Diego, California, United States
View Trial DetailsNCT07436104
Asthma, Asthma (Diagnosis)
Amravati, Maharashtra, India
View Trial DetailsNCT05192265
Infections, Malaria
Ibadan, Oyo State, Nigeria
View Trial Details